No significant effect of orally administered chemokine receptor 1 antagonist on intercellular adhesion molecule-3 expression in relapsing--remitting multiple sclerosis patients

Tools

Item Type:	Article
Title:	No significant effect of orally administered chemokine receptor 1 antagonist on intercellular adhesion molecule-3 expression in relapsing--remitting multiple sclerosis patients
Creators Name:	Reuss, R., Schreiber, V., Klein, A., Infante-Duarte, C., Filippi, M., Pabst, W., Pohl, C. and Oschmann, P.
Abstract:	We investigated the expression of intercellular adhesion molecules ICAM-1 and ICAM-3 on peripheral blood mononuclear cells in a subgroup of 34 patients with relapsing-remitting multiple sclerosis who were treated orally with the chemokine receptor 1 antagonist BX 471 in a 16-week, randomised, double-blind, placebo-controlled phase II study. ICAM-1 and ICAM-3 expression was measured by flow cytometry at different time points during and after therapy and compared using multivariate analysis of variance and non-parametric Mann Whitney test. ICAM-3 expression on CD14( +) peripheral blood mononuclear cells was increased in the verum group under therapy, but did not differ significantly between the verum and placebo groups. Most likely, this trend represents a small epiphenomenon only mediated by receptor cross-talk and feedback mechanisms.
Keywords:	Chemokine Receptor 1 Antagonist, Flow Cytometry, Intercellular Adhesion Molecule-3, MRI, Multiple Sclerosis, Receptor Cross-Talk
Source:	Multiple Sclerosis
ISSN:	1352-4585
Publisher:	Sage Publications
Volume:	16
Number:	3
Page Range:	366-369
Date:	March 2010
Official Publication:	https://doi.org/10.1177/1352458509358188
PubMed:	View item in PubMed

Repository Staff Only: item control page